Global Prostate Cancer Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 197 pages | ID: G5A047EE65FEN
Precision Business Insights (PBI)

Abstracts

Global Prostate Cancer Therapeutics Market

Prostate is an exocrine gland and found only in males. Prostate cancer begins when cells in the prostate gland start to grow uncontrollably. It may spread to other parts of the body mainly bones and lymph nodes. Prostate cancer is the most common type of cancer among the men, but often it can be treated successfully, in initial stages it shows no symptoms but later stages it may produce pain in pelvis, difficulty in urination and furthermore it may cause tiredness and low levels of RBC. The exact cause of prostate cancer is unknown but are generally linked to hereditary causes or to unhealthy diet and lifestyle. Studies suggest that high consumption of red meat and processed meat increases the chances of prostate cancer. Primary risk factors for prostate cancer include obesity, age and family history. Prostate cancer can be diagnosed by biopsy, prostate imaging and various other techniques.

Global prostate cancer therapeutics market is rapidly growing due to increase in incidence of prostate cancer and increase in ageing population. In addition, technological advancements in prostate cancer treatment such as radiation therapy and targeted therapy are expected to boost the prostate cancer therapeutics market. However, patients in underdeveloped and developing regions cannot afford the high costs of treatment and diagnosis of cancer can hinder market growth. In addition to this, low diagnostic rates due to unawareness about prostate cancer symptoms is hampering the prostate cancer therapeutics market.

Global prostate cancer therapeutics market segmented based on route of administration, drug class and distribution channel

Based on drug class prostate cancer therapeutics market is segmented into

• Chemotherapeutic agents
• Immune System Modulators
• Hormones
• Others

Based on route of administration, prostate cancer therapeutics market is segmented into

• Oral
• Parenteral
• Other

Based on distribution channel, prostate cancer therapeutics market is segmented into

• Retail Pharmacy
• Hospital Pharmacy
• Others

New tests such as phi test, 4Kscore test, Progensa, TMPRSS2 ERG and ConfirmMDX will be more accurate in early stage diagnosis. This, in turn, aids in increasing diagnosis rate and consecutively aid in the growth of the market. Prostate cancer therapeutics market has large and small players and market is highly competitive. Players adopting acquisitions, mergers and collaborations to stenghten product offerings in prostate therapeutics market. For instance, in September 2017, Pfizer acquired Medivation, this acquisition represents opportunity to expand the business offering with an attractive pipeline and with xtandi, medicine for men with prostate cancer. Moreover, In April 2016, TESARO, Inc., an oncology-focused biopharmaceutical company, and Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced a global collaboration and license agreement focused on the development and commercialization of niraparib specifically for the treatment of prostate cancer.

Geographically prostate cancer therapeutics market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to have major market share owing to increased research and development, developed healthcare infrastructure and high rate of prostate cancer incidents. In 2017, the American Cancer Society predicts that there will be around 161,360 new diagnoses of prostate cancer and that around 26,730 fatalities will occur because of prostate cancer in America alone. Europe is anticipated to grow at significant rates due to increase in prevalence rates and developed healthcare infrastructure facilities. Asia Pacific region expected to be fastest growing due to developing healthcare infrastructure facilities and increased research and development focused on cancer therapeutics.

Some of the market players in prostate cancer therapeutics market include Johnson & Johnson Services Inc. (U.S.), AbbVie, Inc.(U.S.), Amgen, Inc.(U.S.), AstraZeneca (U.K), Ipsen Group(France), Sanofi (France), Dendreon Corporation (Sanpower Group Co. Ltd.) (U.S.), Bayer AG (Germany) Endo Pharmaceuticals, Inc. (U.S), and Pfizer, Inc (U.S.) to name a few.

In 2016, October, U.S. FDA approved a supplemental new drug application for XTANDI (enzalutamide) capsules of Astellas Pharma Inc. & Pfizer Inc. to treat patients with metastatic xastration resistance prostate cancer

In 2011, Johnson & Johnson has received U.S. FDA approval for ZytIGA used to treat metastatic prostate cancer

Report Outline:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET INTRODUCTION

2.1. Global Prostate Cancer Therapeutics Market – Taxonomy
2.2. Global Prostate Cancer Therapeutics Market –Definitions
  2.2.1. Drug Class
  2.2.2. Route of Administration
  2.2.3. Distribution Channel

3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Prostate Cancer Therapeutics Market Dynamics – Factors Impact Analysis
3.6. Global Prostate Cancer Therapeutics Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
  3.6.4. China
3.7. Global Prostate Cancer Therapeutics Market – Product Innovations

4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Chemotherapeutic Agents
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.1.3. Market Opportunity Analysis
5.2. Immune System Modulators
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.2.3. Market Opportunity Analysis
5.3. Hormones
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.3.3. Market Opportunity Analysis
5.4. Others
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  5.4.3. Market Opportunity Analysis

6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Oral
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.1.3. Market Opportunity Analysis
6.2. Parenteral
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.2.3. Market Opportunity Analysis
6.3. Others
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  6.3.3. Market Opportunity Analysis

7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Retail Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.2.3. Market Opportunity Analysis
7.3. Others
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  7.3.3. Market Opportunity Analysis

8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
  8.5.3. Market Opportunity Analysis
8.6. Global Prostate Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel and Region, 2017 – 2023

9. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Chemotherapeutic agents
    9.1.1.2. Immune System Modulators
    9.1.1.3. Hormones
    9.1.1.4. Others
  9.1.2. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Oral
    9.1.2.2. Parenteral
    9.1.2.3. Others
  9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Retail Pharmacies
    9.1.3.2. Hospital Pharmacies
    9.1.3.3. Others
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Prostate Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
  9.1.6. North America Prostate Cancer Therapeutics Market Dynamics – Trends

10. EUROPE PROSTATE CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Chemotherapeutic agents
    10.1.1.2. Immune System Modulators
    10.1.1.3. Hormones
    10.1.1.4. Others
  10.1.2. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Oral
    10.1.2.2. Parenteral
    10.1.2.3. Others
  10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Retail Pharmacies
    10.1.3.2. Hospital Pharmacies
    10.1.3.3. Others
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Prostate Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
  10.1.6. Europe Prostate Cancer Therapeutics Market Dynamics – Trends

11. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Chemotherapeutic agents
    11.1.1.2. Immune System Modulators
    11.1.1.3. Hormones
    11.1.1.4. Others
  11.1.2. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Oral
    11.1.2.2. Parenteral
    11.1.2.3. Others
  11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Retail Pharmacies
    11.1.3.2. Hospital Pharmacies
    11.1.3.3. Others
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Prostate Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
  11.1.6. Europe Prostate Cancer Therapeutics Market Dynamics – Trends

12. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Chemotherapeutic agents
    12.1.1.2. Immune System Modulators
    12.1.1.3. Hormones
    12.1.1.4. Others
  12.1.2. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Oral
    12.1.2.2. Parenteral
    12.1.2.3. Others
  12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Retail Pharmacies
    12.1.3.2. Hospital Pharmacies
    12.1.3.3. Others
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Prostate Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
  12.1.6. Latin America Prostate Cancer Therapeutics Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA PROSTATE CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Chemotherapeutic agents
    13.1.1.2. Immune System Modulators
    13.1.1.3. Hormones
    13.1.1.4. Others
  13.1.2. Route of administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Oral
    13.1.2.2. Parenteral
    13.1.2.3. Others
  13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Retail Pharmacies
    13.1.3.2. Hospital Pharmacies
    13.1.3.3. Others
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Prostate Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Analysis, Route of Administration, Distribution Channel, and Country, 2017 – 2023
  13.1.6. MEA Prostate Cancer Therapeutics Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Johnson & Johnson Services Inc. (U.S.)
  14.2.2. AbbVie, Inc.(U.S.)
  14.2.3. Amgen, Inc.(U.S.)
  14.2.4. AstraZeneca (U.K)
  14.2.5. Ipsen Group(France)
  14.2.6. Sanofi (France)
  14.2.7. Dendreon Corporation (Sanpower Group Co. Ltd.) (U.S.)
  14.2.8. Bayer AG (Germany)
  14.2.9. Endo Pharmaceuticals, Inc. (U.S)
  14.2.10. Pfizer, Inc (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS